Favrille files $60 million shelf

By Jennifer Chiou

New York, June 20 - Favrille, Inc. registered to sell up to $60 million of securities in an S-3 filing with the Securities and Exchange Commission.

Covered by the shelf are common stock, debt securities and warrants. Securities may be structured as convertibles.

Proceeds will go toward general corporate purposes.

Favrille is a San Diego-based biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.